© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
May 23, 2022
Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.
May 19, 2022
As more and more practices embrace dark adaptation testing, AdaptDx technology has become a staple in primary eye care.
May 12, 2022
Apellis revealed 18-month data for their investigational C3 therapy pegcetacoplan, unveiling continuous lesion growth reduction in eyes with geographic atrophy with monthly and every-other-month injections.
May 07, 2022
The data presented at ARVO showed single subcutaneous doses of D-4517.2 were safe, well-tolerated in healthy subjects.
May 05, 2022
According to the ALOFT study, patients demonstrate improved long-term vision in real-world setting after wet AMD conversion compared to current standard of care.
May 04, 2022
Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.
May 02, 2022
The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.
May 01, 2022
The axitinib intravitreal implant (OTX-TKI) is being evaluated to treat wet age-related macular degeneration in a phase 1b clinical trial.
April 30, 2022
A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.
April 26, 2022
Apellis Pharmaceuticals releases results of their Geographic Atrophy Insights Survey (GAINS), revealing a large emotional toll and significant decrease in independence for patients with geographic atrophy.